Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Easywell Biomedicals EBITDA Margin % Related Terms
Easywell Biomedicals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Easywell Biomedicals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Easywell Biomedicals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Easywell Biomedicals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Easywell Biomedicals (ROCO:1799) has a EBITDA Margin % of 8.40% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Easywell Biomedicals and its competitors. According to the industry distribution chart, Easywell Biomedicals ranks #451 out of 958 companies in the Drug Manufacturers industry, placing it in the top 47.1%.
Is Easywell Biomedicals' EBITDA Margin % too high?
Easywell Biomedicals' current EBITDA Margin % is 8.40%. The Drug Manufacturers industry median EBITDA Margin % is 12.01. Easywell Biomedicals' value of 8.40% is 30% below this industry median. Based on the distribution chart, Easywell Biomedicals ranks #451 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Easywell Biomedicals has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Easywell Biomedicals ranks #451 out of 958 companies for EBITDA Margin %. This puts Easywell Biomedicals in the upper half of its industry. The industry median EBITDA Margin % is 12.01. Easywell Biomedicals' value of 8.40% is 30% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.01, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Easywell Biomedicals's current EBITDA Margin % of 8.40% is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Easywell Biomedicals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Easywell Biomedicals's current EBITDA Margin % is 8.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$88.83, compared to a current price of NT$30.15 — trading 66.1% below its estimated fair value. The current EBITDA Margin % is 8.40% and 30% below the Drug Manufacturers industry median of 12.01. Easywell Biomedicals' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current EBITDA Margin % is 8.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?
Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued.
The current stock price of NT$30.15 is trading 66.1% below its estimated GF Value™ of NT$88.83.
GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.
Key valuation signals for ROCO:1799:
EBITDA Margin %: 8.40%
GF Value™: NT$88.83 vs. price of NT$30.15 (66.1% below fair value)
Industry Position: 30% below the Drug Manufacturers median (#451 of 958)
No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
59GF Score
Get the complete analysis for ROCO:1799
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1799 has been successfully added to your 
